Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) plans to pre-release topline fourth quarter 2025 financial results in the week of January 5, 2026. The pre-release is expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP). Company management will hold in-person investor meetings in San Francisco from January 12–14, 2026 to discuss the topline results. Investors may register for meetings by contacting investor relations at ir@betabionics.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
BBNX was down 2.81% with mixed peer moves: AHCO +1.07%, IART -2.43%, SSII -1.43%, ESTA +0.33%, INMD +0.42%, suggesting stock-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Investor conferences | Neutral | +0.4% | Announcement of November and December 2025 healthcare conference presentations. |
| Oct 28 | Q3 2025 earnings | Positive | +2.2% | Strong Q3 growth, higher margins, and raised full‑year 2025 revenue guidance. |
| Oct 09 | Q3 results timing | Neutral | +0.5% | Scheduling of Q3 2025 results release and earnings call details. |
| Aug 21 | Conference schedule | Neutral | +10.4% | Planned participation in three major healthcare investor conferences in Sept 2025. |
| Jul 29 | Q2 2025 earnings | Positive | +14.3% | Strong Q2 growth, higher gross margin, and raised full‑year 2025 revenue guidance. |
BBNX news has generally seen aligned positive reactions, especially around earnings reports and guidance raises.
Over the last several quarters, Beta Bionics has repeatedly highlighted strong growth in its diabetes device business and frequently raised full‑year revenue guidance, as seen in Q1, Q2, and Q3 2025 earnings releases. Conference participation updates in August and November 2025 also coincided with positive to modestly positive price reactions. Today’s announcement of plans to pre-release topline Q4 2025 results continues this pattern of proactive investor communication around financial performance.
Market Pulse Summary
This announcement signals that Beta Bionics intends to pre-release topline Q4 2025 results the week of January 5, 2026, highlighting metrics such as net sales, new patient starts, and pharmacy benefit plan channel reimbursement. It continues a pattern of detailed earnings communication following multiple guidance raises in 2025. Investors may watch how these topline indicators compare with prior quarters’ growth, as well as any updates shared during the in-person San Francisco meetings from January 12–14, 2026.
AI-generated analysis. Not financial advice.
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP) channel.
Members of the Company’s management team will host in-person meetings in San Francisco from January 12, 2026 through January 14, 2026 to discuss topline fourth quarter 2025 results. The Company invites investors to register for in-person meetings by contacting the Company’s investor relations representative at ir@betabionics.com.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When will Beta Bionics (BBNX) pre-release its Q4 2025 topline results?
What metrics will Beta Bionics (BBNX) include in the Q4 2025 pre-release?
When and where will Beta Bionics (BBNX) management meet investors to discuss Q4 2025 results?
How can investors register for Beta Bionics (BBNX) in-person meetings on January 12–14, 2026?
Will the Beta Bionics (BBNX) pre-release include detailed financial statements?
